---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-052104"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-12-26T23:59:59+00:00"
generated_at: "2026-05-28T23:12:00.690489+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elite Launches Generic Vyvanse (Lisdexamfetamine) in 7 Strengths for ADHD

## Summary
- Elite launched generic lisdexamfetamine (Vyvanse) in 10, 20, 30, 40, 50, 60, 70 mg capsules.
- Branded Vyvanse annual sales ~$4.3B (12 months ending Oct 2024, per IQVIA).
- Product marketed under Elite Laboratories label; company operates cGMP/DEA facility in Northvale, NJ.
- This generic version is indicated for treatment of attention deficit hyperactivity disorder (ADHD).
- Launch represents expansion of Elite's niche generic product portfolio.

## SEC filing metadata
- accession: 0001493152-24-052104
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-12-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224052104/0001493152-24-052104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224052104/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-052104
- JSON: https://secwatch.observer/filing/0001493152-24-052104.json
- Plain text: https://secwatch.observer/filing/0001493152-24-052104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.